SCHEMBL10111145

SCHEMBL10111145

Cc1ccc(C)c(-c2ccc(N(C)C)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
TSHR P16473 2/20 0.54
APP P05067 4/20 0.45
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SNCA P37840 2/20 0.44
TNF P01375 1/20 0.44
NOD1 Q9Y239 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
BCHE P06276 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NSD2 O96028 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6004794 0.84 ESRRA (0.40) ALDH1A1TSHRAPPMEN1KMT2A
SCHEMBL13049645 0.84 ALDH1A1 (0.54) ALDH1A1TSHRAPPALOX15HSD17B10
SCHEMBL30445989 0.83 ESRRA (0.46) ALDH1A1APPMEN1KMT2ATDP1
SCHEMBL1046094 0.83 ESRRA (0.46) ALDH1A1APPMEN1KMT2ANPC1
SCHEMBL139182 0.83 ESRRA (0.46) ALDH1A1APPMEN1KMT2ATDP1
SCHEMBL13714195 0.79 CYP2C19 (0.39) ALDH1A1APPMEN1KMT2ANPC1
SCHEMBL10795565 0.79 ALDH1A1 (0.52) ALDH1A1TSHRAPPALOX15HSD17B10
SCHEMBL14003327 0.78 PGR (0.50) ALDH1A1TSHRAPPHSD17B10SNCA
SCHEMBL24632923 0.77 ALDH1A1 (0.50) ALDH1A1TSHRAPPALOX15HSD17B10
SCHEMBL5447779 0.77 ALDH1A1 (0.49) ALDH1A1TSHRAPPALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9758688-B2 Composition for forming conductive film SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-09-12 US disclosed
US-9704612-B2 Composition of silver-conjugated compound composite SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-07-11 US disclosed
US-9536633-B2 Metallic composite and composition thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-01-03 US disclosed
US-9412487-B2 Silver-(conjugated compound) composite SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-08-09 US disclosed
US-20150275015-A1 COMPOSITION FOR FORMING CONDUCTIVE FILM SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-10-01 US disclosed
US-8866134-B2 Light-emitting device and photovoltaic cell, and method for manufacturing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-10-21 US disclosed
US-20130099224-A1 LIGHT-EMITTING DEVICE AND PHOTOVOLTAIC CELL, AND METHOD FOR MANUFACTURING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-04-25 US disclosed
US-20120168693-A1 SILVER-(CONJUGATED COMPOUND) COMPOSITE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-07-05 US disclosed
US-20120032121-A1 METALLIC COMPOSITE AND COMPOSITION THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-09 US disclosed
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120032121-A1 METALLIC COMPOSITE AND COMPOSITION THEREOF CDH1, EPCAM, CD4 ALDH1A1 932/4885TSHR 3714/4885APP 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.